U.S. Markets closed

Ahead of 1st drug approval, bluebird CEO's pay triples to $24M

Allison DeAngelis
Ahead of 1st drug approval, bluebird CEO's pay triples to $24M

As his company neared the finish line of its first drug approval, bluebird bio CEO Nick Leschly became one of the highest paid life sciences executives in the state.